RARA and acute promyelocytic leukemia: As(III)as the anhydrous form of As(OH)3 (Trisenox, Cell Therapeutics, Seattle, Wash,USA) receivedFDA approval in 2000 as a chemotherapeutic agent for the treatment of APL [117].Acute promyelocytic leukemia (APL) is associated with reciprocal and balancedchromosomal translocations always involving the retinoic acid receptor alpha(RARalpha) gene on chromosome 17 and variable partner genes on distinctchromosomes.